Nivolumab improves the proportion of lung cancer patients alive after more than a year
(ECCO-the European CanCer Organisation) Updated results from the CheckMate 057 phase III clinical trial show that nivolumab continues to show an overall survival benefit compared to docetaxel in patients with non-squamous non-small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 27, 2015 Category: Cancer & Oncology Source Type: news

Nivolumab Survival Benefit Continues in Squamous Cell NSCLCNivolumab Survival Benefit Continues in Squamous Cell NSCLC
Updated results of the CheckMate 017 study show that after 18 months, patients treated with nivolumab continue to have better survival as compared with docetaxel. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Docetaxel in Prostate Cancer -- The Pendulum Swings BackDocetaxel in Prostate Cancer -- The Pendulum Swings Back
Upfront use of docetaxel for prostate cancer has waxed and waned over the years, but recent studies have brought the agent back to the forefront. Medscape Oncology (Source: Medscape Urology Headlines)
Source: Medscape Urology Headlines - September 1, 2015 Category: Urology & Nephrology Tags: Hematology-Oncology Commentary Source Type: news

Adding Early Docetaxel to ADT for Metastatic Prostate Cancer Improves Survival (FREE)
By Kelly Young Edited by Susan Sadoughi, MD Adding early docetaxel to a regimen of androgen-deprivation therapy in patients with prostate cancer is … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 6, 2015 Category: Primary Care Source Type: news

Docetaxel's Up-front Role in Prostate CancerDocetaxel's Up-front Role in Prostate Cancer
Dr David Graham discusses the most clinically relevant research abstract on prostate cancer as presented at ASCO 2015. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 30, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Taxane Benefits in Early Breast Cancer Have Staying PowerTaxane Benefits in Early Breast Cancer Have Staying Power
Long-term clinical trial results support the use of paclitaxel once weekly and docetaxel once every 3 weeks following chemotherapy in women with stage II or III operable breast cancer. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

NICE recommends Boehringer’s nintedanib plus docetaxel to treat NSCLC
Boehringer Ingelheim has announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended company’s Vargatef (nintedanib) in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) within t… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 3, 2015 Category: Pharmaceuticals Source Type: news

ASCO: Survival Benefit With Docetaxel in High-Risk Prostate Cancer
(MedPage Today) -- For the first time, adjuvant chemotherapy improves survival in the localized setting (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - June 1, 2015 Category: Geriatrics Source Type: news

New Immune Therapies Show Major Promise In Shrinking Cancer Tumors
CHICAGO (AP) — For the first time, a major study shows that a drug targeting the body's disease-fighting immune system may improve survival for the most common form of lung cancer. These newer kinds of drugs have transformed treatment of melanoma, the deadliest kind of skin cancer. Studies presented at a conference Friday suggest these "immune therapies" can play a broader role in more common cancers, including lung, liver, colon and head and neck. Doctors also may have found a way to help predict which patients would respond best to one of these newer treatments, according to research presented at the Chicago meeting....
Source: Science - The Huffington Post - June 1, 2015 Category: Science Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - June 1, 2015 Category: Pharmaceuticals Source Type: news

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy
Roche today announced new results from the Phase II NeoSphere study. The results suggest that Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and docetaxel chemotherapy given prior to surgery reduced the risk of disease getting worse and increased the time people lived without their cancer returning compared to Herceptin and chemotherapy in people with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - June 1, 2015 Category: Pharmaceuticals Source Type: news

Adding Chemo Boosts Prostate Cancer SurvivalAdding Chemo Boosts Prostate Cancer Survival
A federally funded phase 3 clinical trial provides more evidence supporting the addition of docetaxel chemotherapy to standard hormone and radiation treatment in men with high-risk disease. Medscape News Slideshows (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 30, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Nivolumab in Lung Cancer Shows 'Unprecedented' Survival Nivolumab in Lung Cancer Shows 'Unprecedented' Survival
Another phase 3 study has shown a survival benefit for the immunotherapy nivolumab compared with chemotherapy with docetaxel. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 30, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Nivolumab in Lung Cancer Shows Unprecedented Survival Nivolumab in Lung Cancer Shows Unprecedented Survival
Another phase 3 study has shown a survival benefit for the immunotherapy nivolumab compared with chemotherapy with docetaxel. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 30, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASCO: Chemo-ADT Combo Still Winning in Prostate Cancer
(MedPage Today) -- Yet another report of survival improvement with upfront docetaxel plus hormonal therapy. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - May 14, 2015 Category: Geriatrics Source Type: news